Castration-refractory prostate cancer: New drugs in the pipeline.
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
Department of Hemato-Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, B-2020 Antwerp, Belgium. dirk.schrijvers@zna.be
Dirk
D
Schrijvers
Peter
P
Van Erps
Jim
J
Cortvriend
D000726:Androgen Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016232:Endothelins / Q000037:antagonists & inhibitors; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000503:physiopathology
D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016232:Endothelins; D007155:Immunologic Factors